NTRK1 and neuroblastoma: Abnormal activated TRK proteins including those with mutations, overexpression and fusion, have been detected and characterized as oncogenic drivers in a large variety of cancers including colorectal cancer, lung cancers, melanoma, acute myeloid leukemia, neuroblastoma, breast cancer and cutaneous cancers [4,5,6].